Pomerantz Law Firm Announces the Filing of a Class Action Against 3D Systems Corporation and Certain Officers

Core Viewpoint - A class action lawsuit has been filed against 3D Systems Corporation and certain officers for alleged violations of federal securities laws during the Class Period from August 13, 2024, to May 12, 2025, seeking damages for misleading statements regarding the company's business and operations [1][8]. Company Overview - 3D Systems provides 3D printing and digital manufacturing solutions across various regions, earning revenue from two segments: Healthcare Solutions and Industrial Solutions [4]. - The Healthcare Solutions segment includes dental, medical devices, personalized health services, and a Regenerative Medicine Program focused on 3D printing organs for transplantation [4][5]. Financial Performance - In March 2025, 3D Systems projected revenue for 2025 to be between $420 million and $435 million, indicating flat to modest growth, with a non-GAAP Gross Profit Margin of 37% to 39% and non-GAAP Operating Expense of $200 million to $220 million [7]. - The company reported a Q4 2024 non-GAAP earnings-per-share of -$0.19, missing estimates, and a sales revenue of $111 million, down 3.4% year-over-year [9]. - For full-year 2024, sales were reported at $440.1 million, a 10% decrease from the previous year, attributed to lower hardware systems sales due to macroeconomic factors [9]. - In Q1 2025, revenue was $94.5 million, down 8% year-over-year, with a net loss of $37 million, more than doubling the loss from Q1 2024 [10]. Market Reaction - Following the announcement of disappointing financial results, 3D Systems' stock price fell significantly, dropping 20.96% to $2.15 per share on March 27, 2025, and further declining 26.6% to $1.87 per share on May 13, 2025 [9][11]. Allegations in Lawsuit - The lawsuit alleges that during the Class Period, the defendants made materially false and misleading statements about the company's business resilience and the impact of weakened customer spending, as well as failing to disclose the negative effects of updated milestone criteria on the Regenerative Medicine Program revenue [8].